<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207245626
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        UNISIA 8 MG/2.5 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8,2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        67
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Unisia contains the two active ingredients amlodipine besylate and candesartan cilexetil. Both active ingredients help control high blood pressure.</p><ul><li>Amlodipine belongs to the group of medicines called calcium antagonists. Amlodipine prevents calcium from getting into the vascular walls, thereby preventing the narrowing of the blood vessels.</li><li>Candesartan belongs to the group of medicines called angiotensin II receptor antagonists. Angiotensin II is produced by the body and causes blood vessels to constrict, resulting in increased blood pressure. Candesartan works by blocking the effects of angiotensin II.</li></ul><p>Tis means that both active ingredients help to stop constriction of the blood vessels. As a result, the blood vessels relax and blood pressure is lowered.</p><p>Unisia is used to treat high blood pressure in patients whose blood pressure is already controlled through the combination of the two ingredients amlodipine and candesartan separately in the same dosage</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Unisia </strong></p><ul><li>If you are allergic to candesartan cilexetil, amlodipine besylate, or other calcium antagonists or any of the other ingredients of this medicine listed in section 6,</li><li>If you suffer from extremely low blood pressure (hypotension),</li><li>If you suffer from severe narrowing of the left ventricular outflow tract (aortic stenosis) or cardiogenic shock (where your heart can no longer supply the body with sufficient blood),</li><li>If you have heart failure following a heart attack,</li><li>If you are more than three months pregnant. (Taking Unisia is also not recommended in the early stages of pregnancy, see section &quot;Pregnancy and breast-feeding&quot;),</li><li>If you have severe liver disease or cholestasis (a condition blocking bile from flowing out of the gallbladder),</li><li>If you have diabetes mellitus or reduced kidney function and are being treated with a blood pressure lowering medicine containing aliskiren.</li></ul><p><strong>Warnings and precautions </strong></p><p>Please talk to your doctor or pharmacist before taking Unisia if any of the following apply to you or have ever applied to you:</p><ul><li>If you have recently had a heart attack,</li><li>If you have heart failure,</li><li>If you suffer from a severe increase in blood pressure (hypertensive crisis),</li><li>If you have low blood pressure (hypotension),</li><li>If you are older and your dose needs to be increased,</li><li>If you have liver or kidney problems or are a dialysis patient,</li><li>If you have recently had a kidney transplant,</li><li>If you need to vomit, have recently experienced violent vomiting, or have diarrhea,</li><li>If you have a condition of the adrenal glands called Conn&#39;s syndrome (also called primary hyperaldosteronism),</li><li>If you have ever had a stroke,</li><li>If you are due to be given a medicine for anesthesia/numbing (anesthetic). This could be for surgical procedures or any type of dental treatment,</li><li>If you are taking any of the following medicines to treat high blood pressure:<ul><li>An ACE inhibitor (e.g., enalapril, lisinopril, ramipril), especially if you have kidney problems due to diabetes mellitus,&nbsp;</li><li>Aliskiren.</li></ul></li></ul><p>If necessary, your doctor will check your kidney function, blood pressure and electrolyte levels (e.g. potassium) in your blood at regular intervals. See also the section &quot;Do not take Unisia&quot;.</p><p>Tell your doctor if you suspect you are (or may become) pregnant. Taking Unisia early in pregnancy is not recommended, and Unisia should not be taken after the third month of pregnancy, since taking candesartan cilexetil/amlodipine besylate at this stage may cause serious harm to your unborn child (see section &#39;Pregnancy and breast-feeding&#39;).</p><p><strong>Children and adolescents</strong></p><p>There is no experience with the use of candesartan cilexetil/amlodipine besylate in children (under 18 years of age). Therefore, this medicine should not be given to children or adolescents.</p><p><strong>Other medicines and Unisia</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, or if you are planning to take or use any other medicines.</p><p>Unisia may affect other medicines or be affected by other medicines. Your doctor may need to adjust your dosage and/or take other precautions if you are taking/using the following medicines:</p><ul><li>Ketoconazole, itraconazole (for fungal diseases),</li><li>Ritonavir, indinavir, nelfinavir (so-called protease inhibitors for HIV infection),</li><li>Rifampicin, erythromycin, clarithromycin (antibiotics - for bacterial infections),</li><li>Hypericum perforatum (St. John&#39;s wort),</li><li>Verapamil, diltiazem (heart medication),</li><li>Dantrolene (an infusion for severe impairment of body temperature),</li><li>Tacrolimus, sirolimus, temsirolimus and everolimus (to control the body&rsquo;s immune response; to prevent the body from rejecting an organ transplant),</li><li>Simvastatin (a cholesterol-lowering drug),</li><li>Cyclosporine (a drug used to suppress the immune system),</li><li>Other medicines that help lower your blood pressure, including beta-blockers; and diazoxide,</li><li>An ACE inhibitor or aliskiren (see also sections &ldquo;Do not take Unisia&rdquo; and &ldquo;Warnings and precautions&rdquo;),</li><li>Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines used to relieve pain and inflammation),</li><li>Acetylsalicylic acid (medicine used to relieve pain and inflammation) if you take more than 3 g per day,</li><li>Potassium preparations or potassium-containing salt substitutes (medicines that increase the amount of potassium in your blood),</li><li>Heparin (a medicine used to thin the blood),</li><li>Cotrimoxazole (an antibiotic), also known as trimethoprim/sulfamethoxazole,</li><li>Water tablets (diuretics),</li><li>Lithium (a medicine for mental illness).</li></ul><p><strong>Unisia with food and drink</strong></p><p>People taking Unisia should not eat grapefruit or drink grapefruit juice, as this can increase levels of the active ingredient amlodipine in the blood, possibly leading to an uncontrolled intensification of the blood pressure-lowering effects of Unisia.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, or if you suspect you may be pregnant or intend to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.</p><p><em>Pregnancy</em></p><p>Tell your doctor if you suspect you are (or may become) pregnant. Your doctor will usually advise you to stop taking Unisia before you become pregnant or as soon as you know you are pregnant, and will recommend another medicine. Taking Unisia early in pregnancy is not recommended, and Unisia should not be taken after the third month of pregnancy, as taking candesartan cilexetil/amlodipine besylate at this stage may cause serious harm to your unborn child.</p><p><em>Breast-feeding</em></p><p>Amlodipine passes into breast milk in small amounts. If you are breast-feeding or plan to start breast-feeding soon, please notify your doctor before taking Unisia. Unisia is not recommended for use by mothers who are breast-feeding; your doctor may choose a different treatment for you if you want to breast-feed, especially while your child is in the newborn stage or if it was premature.</p><p><strong>Driving and using machines </strong></p><p>The ability to actively engage in road traffic or operate machines may be adversely affected by Unisia. If the tablets make you feel sick, dizzy or tired, or if you experience headaches, do not drive or operate machinery, and consult your doctor immediately.</p><p><strong>Unisia</strong><strong> </strong><strong>contains sodium &nbsp;</strong></p><p>Unisia contains sodium. Each tablet contains 0.57 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has directed. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is 1 tablet of Unisia 8 mg/2.5 mg or 8 mg/5 mg once daily. You can take Unisia with or without food.</p><p><strong>If you take more </strong><strong>Unisia </strong><strong>than you should</strong></p><p>If you have taken too many tablets, your blood pressure may drop or become dangerously low. You may feel dizzy, lightheaded, and weak. If the drop in blood pressure is severe enough, shock may occur. Your skin may then feel cold and damp and you may lose consciousness. Seek medical attention immediately if you have taken too many tablets.</p><p>Excess fluid may accumulate in your lungs (pulmonary oedema) causing shortness of breath that may develop up to 24-48 hours after intake.</p><p><strong>If you forget to take </strong><strong>Unisia</strong></p><p>If you forget to take a tablet, skip this dose completely. Then take the next dose at the usual time. Do not take a double dose to make up for a missed dose.</p><p><strong>If you stop taking </strong><strong>Unisia</strong></p><p>Your doctor will tell you how long you should take your medicine. If you stop taking your medicine before he has asked you to, your symptoms may return. Do not stop taking Unisia without first talking to your doctor.</p><p>If you have any further questions about taking this medicine, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Talk to your doctor immediately if you experience the following very rare, serious side effects after taking this medicine:</strong></p><ul><li>Sudden wheezing when breathing, chest pain, shortness of breath, or breathing difficulties</li><li>Swelling of the eyelids, face or lips</li><li>Swelling of the tongue or throat, causing severe difficulty breathing</li><li>Severe skin reactions including intense rash, hives, skin reddening all over the body, severe itching, blistering, peeling or swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions</li><li>Heart attack, irregular heartbeat</li><li>Pancreatitis, which can lead to severe abdominal and back pain making you feel extremely unwell.</li></ul><p>Candesartan cilexetil/amlodipine besylate may cause a decrease in the number of white blood cells. Your resistance to infection may be reduced and you may notice fatigue, infection, or fever. If this occurs, talk to your doctor. Your doctor may occasionally do blood tests to check whether candesartan cilexetil/amlodipine besylate has had any effect on your blood (agranulocytosis).</p><p><strong>Other potential side effects</strong></p><p>Since candesartan cilexetil/amlodipine besylate is a combination of two active ingredients, the reported side effects are the result of taking either amlodipine or candesartan.</p><p><strong><em>Side effects associated with taking amlodipine</em></strong></p><p><strong>Very common (may affect more than 1 in 10 patients)</strong></p><ul><li>Fluid accumulation in the body (edema)</li></ul><p><strong>Common (may affect up to 1 in 10 patients) </strong></p><ul><li>Headache, dizziness, drowsiness (especially at the beginning of treatment)</li><li>Palpitations, reddening of the skin with a feeling of warmth</li><li>Abdominal pain, nausea</li><li>Changes in bowel habits, diarrhea, constipation, indigestion</li><li>Fatigue, weakness</li><li>Visual disturbances, double vision</li><li>Muscle cramps</li><li>Ankle swelling.</li></ul><p><strong>Uncommon (may affect up to 1 in 100 patients)</strong></p><ul><li>Mood swings, anxiety, depression, insomnia</li><li>Tremors, impaired taste, brief loss of consciousness</li><li>Reduced sensitivity to touch or tingling in the extremities, loss of pain sensation</li><li>Ringing in the ears</li><li>Low blood pressure</li><li>Sneezing/runny nose due to inflammation of the nasal mucosa (rhinitis)</li><li>Cough</li><li>Dry mouth, vomiting</li><li>Hair loss, increased sweating, skin itching (pruritus), red patches on the skin, skin discoloration</li><li>Difficulty urinating, increased nocturnal urination, more frequent urination</li><li>Erectile dysfunction, discomfort in the mammary glands or enlargement of the mammary glands in men</li><li>Pain, malaise</li><li>Joint or muscle pain, back pain</li><li>Weight gain or weight loss</li></ul><p><strong>Rare (may affect up to 1 in 1,000 patients)</strong></p><ul><li>Confusion.</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 patients)</strong></p><ul><li>Decrease in white blood cells, decrease in platelets, which may cause unusual bruising or easy bleeding</li><li>Increased blood sugar levels (hyperglycemia)</li><li>Nerve disturbances that can cause muscle weakness, decreased sensitivity to touch or tingling</li><li>Swollen gums</li><li>Distended abdomen (gastritis)</li><li>Liver dysfunction, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), elevated liver enzymes, which can affect certain medical tests</li><li>Increased muscle tension</li><li>Inflammatory response in blood vessels, often associated with skin rash</li><li>Sensitivity to light.</li></ul><p><strong>Not known (frequency cannot be estimated on the basis of the available data) </strong></p><ul><li>Trembling, stiffness, mask-like face, slow movements and shuffling, unbalanced gait.</li></ul><p><strong><em>Side effects associated with the use of candesartan</em></strong></p><p><strong>Common (may affect up to 1 in 10 patients)</strong></p><ul><li>Dizziness/spinning sensation (vertigo)</li><li>Headache</li><li>Respiratory infection</li><li>Low blood pressure. This may cause you to feel faint or dizzy</li><li>Changes in blood test results: elevated level of potassium in your blood, especially if you already have kidney problems or heart failure. In severe cases, you may notice fatigue, weakness, irregular heartbeat, or tingling (&quot;formication&quot;)</li><li>&nbsp;Effects on kidney function, especially if you already have kidney problems or heart failure. In very rare cases, kidney failure may occur.</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 patients) </strong></p><ul><li>Swelling of the face, lips, tongue and/or throat</li><li>Decrease in your red or white blood cells. You may notice fatigue, infection, or fever</li><li>Skin rash, blistering rash (hives)</li><li>Itching (pruritus)</li><li>Back, joint or muscle pain</li><li>Changes in your liver function, including liver inflammation (hepatitis). You may notice fatigue, yellowing of your skin and the whites of your eyes, as well as flu-like symptoms</li><li>Cough</li><li>Nausea</li><li>Changes in blood test results: reduced level of sodium in your blood. In severe cases, you may notice weakness, lack of energy, or muscle cramps.</li></ul><p><strong>Not known (frequency cannot be estimated on the basis of the available data)</strong></p><ul><li>Diarrhea.</li></ul><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, healthcare provider or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are candesartan cilexetil and amlodipine besylate.</p><p>Each tablet of Unisia 8 mg/2.5 mg Tablets contains 8 mg candesartan cilexetil and 3.47 mg amlodipine besylate equivalent to 2.5 mg amlodipine.</p><p>Each tablet of Unisia 8 mg/5 mg Tablets contains 8 mg candesartan cilexetil and 6.93 mg amlodipine besylate equivalent to 5 mg amlodipine.</p><p>The other ingredients are mannitol, hydroxy propyl cellulose, microcrystalline cellulose, polyethylene glycol, croscarmellose sodium, magnesium stearate, yellow iron oxide (in Unisia 8 mg/2.5 mg Tablets only) and red iron oxide (in Unisia 8 mg/5 mg Tablets only).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Unisia 8 mg/2.5 mg Tablets are light yellow capsule-shaped tablets, embossed with “JI” on one side and “152” on the other side in orange PVC/Aclar-aluminum blisters.
Unisia 8 mg/5 mg Tablets are light red capsule-shaped tablets, embossed with “JI” on one side and “153” on the other side in orange PVC/Aclar-aluminum blisters.  
Pack size: 30 Tablets (3 blisters; each blister contains 10 tablets). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Batch releaser and Bulk manufacturer </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Under licensed from </strong></p><p>Takeda Pharmaceutical Company Ltd.</p><p>Osaka - Japan</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp; United Arab of Emirates</p><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 08/2023; version number Un3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي يونيجيا على المادتين الفعالتين أملوديبين بيسيلات والكانديسارتان سيليكسيتيل. وكلا المادتان الفعالتان تساعدان في التحكم في ضغط الدم المرتفع.</p><ul dir="rtl"><li>ينتمي الأملوديبين ضمن مجموعة الأدوية المعروفة باسم مناهضات الكالسيوم. ويمنع الأملوديبين وصول الكالسيوم إلى جدران الأوعية الدموية، وبالتالي يمنع تضيق الأوعية الدموية.</li><li>ينتمي الكانديسارتان ضمن مجموعة الأدوية المعروفة باسم مناهضات مستقبلات الأنجيوتينسن II. يتكون الأنجيوتينسن II في الجسم، ويتسبب في تضيق الأوعية الدموية، وبالتالي ارتفاع ضغط الدم. يعمل الكانديسارتان على منع تأثير الأنجيوتينسن II.</li></ul><p dir="RTL">هذا يعني أن المادتين الفعالتين تساعدان في إيقاف تضيق الأوعية الدموية. ونتيجةً لذلك تسترخي الأوعية الدموية، وينخفض ضغط الدم.</p><p dir="RTL">يتم استخدام يونيجيا لمعالجة ارتفاع ضغط الدم لدى المرضى الذين يمكن التحكم في ضغط الدم لديهم عن طريق الجمع بين المادتين الفعالتين المنفردتين الأملوديبين والكانديسارتان في نفس الجرعة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول يونيجيا</strong></p><ul dir="rtl"><li>إذا كانت لديك حساسية لكانديسارتان سيليكسيتيل، أملوديبين بيسيلات، أو غيره من مناهضات الكالسيوم أو أي مكوّن أخرى من مكونات هذا الدواء المذكورة في القسم 6،</li><li>إذا كنت تعاني من انخفاض حاد في ضغط الدم (ضغط الدم المنخفض)،</li><li>إذا كنت تعاني من ضيق شديد في مجرى تدفق البطين الأيسر (تضيق الصمام الأبهري) أو تعاني من صدمة قلبية (بحيث لا يمكن لقلبك إمداد الجسم بالدم الكافي)،&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>إذا كنت تعاني من فشل القلب بعد نوبة قلبية،</li><li>إذا كنتِ حاملاً لأكثر من ثلاثة أشهر. (يُنصح بعدم تناول يونيجيا أيضًا في المراحل المبكرة من الحمل، انظري قسم &quot;الحمل والرضاعة&quot;).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>إذا كنت تعاني من مرض كبدي شديد أو ركود صفراوي (حالة تمنع تدفق الصفراء من المرارة)،</li><li>إذا كنت تعاني من مرض السكري أو ضعف في وظائف الكلى وتتعالج باستخدام أدوية خفض ضغط الدم التي تحتوي على أليسكيرين.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">يُرجى التحدث مع طبيبك أو الصيدلي قبل تناول يونيجيا، إذا كان أحد الشروط التالية ينطبق عليك أو سبق أن تعرضت له:</p><ul dir="rtl"><li>إذا أصبت بنوبة قلبية مؤخرًا، &nbsp;</li><li>إذا كنت تعاني من فشل القلب،</li><li>إذا كنت تعاني من ارتفاع شديد في ضغط الدم (أزمة ارتفاع ضغط الدم)،</li><li>إذا كنت تعاني من انخفاض في ضغط الدم (ضغط الدم المنخفض)، &nbsp;</li><li>إذا كنت مُسنًا ويجب زيادة جرعتك،</li><li>إذا كنت تعاني من مشاكل في الكبد أو الكلى أو تقوم بغسيل الكلى، &nbsp;</li><li>إذا قمت بزرع كلية مؤخرًا، &nbsp;</li><li>إذا كنت مضطرًا للتقيؤ، أو تقيأت مؤخرًا بشدة، أو كنت تعاني من الإسهال، &nbsp;</li><li>إذا كنت تعاني من مرض في الغدة الكظرية، تسمى متلازمة كون (يُطلق عليه أيضًا اسم فرط الألدوستيرونية الأولية)، &nbsp;</li><li>إذا سبق وتعرضت لسكتة دماغية، &nbsp;</li><li>إذا كان يجب إعطائك دواء للتخدير (مخدر). يمكن أن يكون للعمليات الجراحية أو أي نوع من معالجات الأسنان، &nbsp;</li><li>إذا كنت تتناول أحد الأدوية التالية لعلاج ضغط الدم المرتفع: &nbsp;<ul><li>مثبط إنزيم محول الأنجيوتنسين (مثل إنالابريل، ليزينوبريل، راميبريل)، خصوصًا إذا كنت تعاني من مشاكل في الكلى الناجمة عن مرض السكري،</li><li>أليسكيرين.</li></ul></li></ul><p dir="RTL">إذا كان ضرورياً، سوف يقوم طبيبك بفحص وظائف الكلى، ضغط الدم ومستويات الإلكتروليت (مثل البوتاسيوم) في دمك، على فترات منتظمة.</p><p dir="RTL">انظر أيضاً قسم &quot;لا تتناول يونيجيا&quot;.</p><p dir="RTL">أخبري طبيبك إذا كنتِ تعتقدين أنك حامل (أو يمكن أن تصبحي حاملاً). لا يُنصح بتناول يونيجيا في المراحل المبكرة للحمل، ويجب عدم تناوله بعد الشهر الثالث من الحمل، لأن تناول كانديسارتان سيليكسيتيل/أملوديبين بيسيلات في هذه المرحلة قد يؤدي إلى أضرار خطيرة بالجنين (انظري قسم &quot;الحمل والرضاعة&quot;).</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا توجد تجربة لاستخدام كانديسارتان سيليكسيتيل/أملوديبين بيسيلات من قِبل الأطفال (أقل من 18 عامًا). لذلك، لا يُسمح بإعطاء هذا الدواء للأطفال والمراهقين.</p><p dir="RTL"><strong>الأدوية الأخرى ويونيجيا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي، إذا كنت تأخذ أو أخذت مؤخرًا أي أدوية أخرى، أو إذا كنت تخطط لتناول أو استخدام أي أدوية أخرى.</p><p dir="RTL">قد يؤثر يونيجيا على الأدوية الأخرى أو يتأثر بها. يجب على طبيبك تعديل جرعتك و/أو اتخاذ تدابير احترازية أخرى، إذا كنت تتناول/تستخدم الأدوية التالية:</p><ul dir="rtl"><li>كيتوكونازول، إيتراكونازول (للأمراض الفطرية)،</li><li>ريتونافير، إندينافير، نلفينافير (ما يُسمى بمثبطات البروتياز يستخدم لعدوى فيروس نقص المناعة البشرية)،</li><li>ريفامبيسين، إريثروميسين، كلاريثروميسين (مضادات حيوية - مضادة للعدوى البكتيرية)،</li><li>العَرَن المثقوب (نبتة سانت جون)،</li><li>فيراباميل، ديلتيازيم (دواء للقلب)،</li><li>دانترولين (تسريب يُستخدم مع الاضطرابات الشديدة في درجة حرارة الجسم)،</li><li>تاكروليموس، سيروليموس، تيمسيروليموس، إيفيروليموس (للتحكم في الاستجابة المناعية للجسم؛ لمنع الجسم من رفض العضو المزروع)،</li><li>سيمفاستاتين (دواء مخفض للكوليسترول)،</li><li>سيكلوسبورين (دواء لكبت جهاز المناعة)،</li><li>الأدوية الأخرى التي تساعد على خفض ضغط الدم، بما في ذلك حاصرات بيتا؛ وديازوكسيد،</li><li>مثبط إنزيم محول الأنجيوتنسين أو أليسكيرين (انظر قسم &quot;لا تتناول يونيجيا&quot;، و&quot;الاحتياطات والتحذيرات&quot;)،</li><li>الأدوية غير الستيرويدية المضادة للالتهابات مثل إيبوبروفين، نابروكسين، ديكلوفيناك، سيليكوكسيب، إيتوريكوكسيب (أدوية تستخدم لتخفيف الألم والالتهاب)،</li><li>حمض الأسيتيل ساليسيليك (دواء يستخدم لتخفيف الألم والالتهاب)، في حالة تناول أكثر من 3 غم في اليوم،</li><li>مستحضرات البوتاسيوم أو بدائل الملح المحتوية على البوتاسيوم (أدوية تزيد من كمية البوتاسيوم في الدم)،</li><li>هيبارين (دواء لترقيق الدم)،</li><li>كوتريموكسازول (مضاد حيوي)، يُعرف أيضًا باسم تريميثوبريم/سلفاميثوكسازول،</li><li>أقراص الماء (مدرات البول)،</li><li>ليثيوم (دواء للأمراض النفسية).</li></ul><p dir="RTL"><strong>يونيجيا مع الطعام والشراب</strong></p><p dir="RTL">يجب على الأشخاص الذين يتناولون يونيجيا عدم أكل الجريب فروت أو شرب عصير الجريب فروت، لأنه يمكن أن يرفع من مستوى الدم للمادة الفعالة أملوديبين، ما قد يؤدي إلى زيادة غير متحكم فيها لتأثير يونيجيا المخفض لضغط الدم.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعاً، أو إذا كنت تعتقدين أنك حامل أو تخططين للحمل، فاستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><em>الحمل</em></p><p dir="RTL">أخبري طبيبك إذا كنتِ تعتقدين أنك حامل (أو يمكن أن تصبحي حاملاً). في المعتاد يوصي الطبيب بالتوقف عن تناول يونيجيا قبل أن تصبحي حاملاً أو بمجرد معرفتك بأنك حامل، وينصحك بدواء آخر. لا يُنصح باستخدام يونيجيا في بداية الحمل، ويجب عدم تناوله بعد الشهر الثالث من الحمل، لأن تناول كانديسارتان سيليكسيتيل/أملوديبين بيسيلات في هذه المرحلة قد يؤدي إلى أضرار خطيرة بالجنين.</p><p dir="RTL"><em>الرضاعة</em></p><p dir="RTL">يمر الأملوديبين إلى حليب الأم بكميات ضئيلة. إذا كنتِ ترضعين أو تخططين للبدء في الإرضاع قريبًا، فأخبري طبيبك بذلك قبل تناول يونيجيا. لا يُنصح بتناول يونيجيا للأمهات المرضعات؛ يمكن لطبيبك اختيار علاج آخر لك، إذا كنتِ ترغبين في الإرضاع، وبالأخص إذا كان طفلك حديث الولادة أو وُلِد مبكرًا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يؤثر يونيجيا سلبًا في القدرة على المشاركة بشكل فعّال في حركة المرور أو استخدام الآلات. إذا كانت الأقراص تُشعرك بالمرض، بالدوار أو التعب، أو تعاني من الصداع، فلا تقد السيارة ولا تستخدم أي آلات، واستشر طبيبك على الفور.</p><p dir="RTL"><strong>يحتوي يونيجيا على الصوديوم </strong></p><p dir="RTL">يحتوي يونيجيا على الصوديوم. يحتوي كل قرص على 0.57 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا حسب تعليمات الطبيب أو الصيدلي تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من يونيجيا 8 ملغم/2.5 ملغم أو 8 ملغم/5 ملغم مرة واحدة يومياً. يمكن تناول يونيجيا مع أو بدون الطعام.</p><p dir="RTL"><strong>إذا تناولت يونيجيا أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت العديد من الأقراص، فمن الممكن أن ينخفض ضغط الدم لديك أو قد يقل بدرجة خطيرة. يمكن أن تشعر بالدوخة، الدوار، والضعف. عندما ينخفض ضغط الدم بشدة من الممكن أن تحدث صدمة. قد تشعر بجلدك باردًا ورطبًا، وقد تفقد وعيك. اطلب الإشراف الطبي على الفور إذا تناولت العديد من الأقراص.</p><p dir="RTL">السائل الزائد قد يتراكم في رئتيك )الوذمة&nbsp;الرئوية) الذي يؤدي إلى ضيق في التنفس الذي من الممكن أن يتطور حتى 24-48 ساعة بعد تناول الدواء.<strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول يونيجيا </strong></p><p dir="RTL">إذا نسيت تناول أحد الأقراص، تخطى هذه الجرعة تمامًا. ثم تناول الجرعة التالية في الموعد المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>إذا توقفت عن تناول يونيجيا </strong></p><p dir="RTL">سيخبرك طبيبك بالمدة التي يجب أن تتناول فيها الدواء. إذا أنهيت استخدام الدواء قبل أن يطلب منك الطبيب ذلك، فمن الممكن أن تعاودك لك الأعراض. لذا لا توقف تناول يونيجيا دون التحدث أولاً إلى الطبيب.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، يُرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية قد يكون لهذا الدواء أيضًا آثار جانبية، لكنها لا تحدث بالضرورة لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>تحدث إلى طبيبك على الفور إذا ظهرت لديك أي من الآثار الجانبية الخطيرة والنادرة جدًا التالية بعد تناول هذا الدواء</strong><strong>:</strong></p><ul dir="rtl"><li>صفير مفاجئ عند التنفس، ألم في الصدر، ضيق تنفس، أو صعوبات تنفس</li><li>انتفاخات الجفون، الوجه أو الشفتين</li><li>انتفاخات اللسان أو الحلق، ما يؤدي إلى صعوبات شديدة في التنفس</li><li>تفاعلات جلدية شديدة بما في ذلك الطفح الجلدي الشديد، الشَّرَى، احمرار الجلد في جميع أنحاء الجسم، الحكة الشديدة، نفطات، تقشير الجلد وتورمه، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) أو تفاعلات حساسية أخرى</li><li>نوبة قلبية، نبضات قلب غير منتظمة</li><li>التهاب البنكرياس، الذي يمكن أن يؤدي إلى آلام شديدة في المعدة والظهر مع الشعور بتوعك حاد</li></ul><p dir="RTL">يمكن أن يسبب كانديسارتان سيليكسيتيل/أملوديبين بيسيلات في انخفاض عدد خلايا الدم البيضاء. وقد تقل قدرتك على مقاومة العدوى وربما تشعر بالإرهاق، العدوى، أو الحمى. في حالة حدوث هذا الأمر، يُرجى التواصل مع طبيبك. في بعض الأحيان، قد يطلب منك طبيبك إجراء فحوصات دم للتحقق من مدى تأثير كانديسارتان سيليكسيتيل/أملوديبين بيسيلات في دمك (ندرة المحببات).</p><p dir="RTL"><strong>آثار جانبية أخرى محتملة</strong></p><p dir="RTL">نظرًا لأن كانديسارتان سيليكسيتيل/أملوديبين بيسيلات عبارة عن تركيبة من مادتين فعالتين، فإن الآثار الجانبية المبلغ عنها تعود إلى تناول الأملوديبين أو الكانديسارتان.</p><p dir="RTL"><strong><em>الآثار الجانبية المرتبطة بتناول الأملوديبين</em></strong></p><p dir="RTL"><strong>شائعة جداً (قد تحدث لأكثر من 1 من كل 10 مرضى)</strong></p><ul dir="rtl"><li>تراكم السوائل في الجسم (وَذَمَة)</li></ul><p dir="RTL"><strong>شائعة (قد تحدث لدى 1 من كل 10 مرضى)</strong></p><ul dir="rtl"><li>صداع، دوخة، نعاس (خصوصًا في بداية العلاج)</li><li>خفقان، احمرار الجلد مع الشعور بالدفء</li><li>ألم في المعدة، غثيان</li><li>تغير عادات تفريغ الأمعاء، إسهال، إمساك، عسر الهضم</li><li>إرهاق، ضعف</li><li>اضطرابات في الرؤية، الرؤية المزدوجة</li><li>تشنجات عضلية</li><li>تورمات الكاحل.</li></ul><p dir="RTL"><strong>غير شائعة (قد تحدث لدى 1 من كل 100 مريض)</strong></p><ul dir="rtl"><li>تقلبات مزاجية، قلق، اكتئاب، أرق</li><li>قشعريرة، اضطرابات في التذوق، فقدان قصير للوعي</li><li>حساسية منخفضة للمس أو تنميل في الأطراف، فقدان الشعور بالألم</li><li>طنين في الأذنين</li><li>ضغط دم منخفض</li><li>العطس/سيلان الأنف الناجم عن التهاب الغشاء المخاطي للأنف (التهاب الأنف)</li><li>سعال</li><li>جفاف الفم، القيء</li><li>تساقط الشعر، زيادة التعرق، حكة في الجلد، بقع حمراء على الجلد، تغير لون الجلد</li><li>صعوبة في التبول، زيادة الرغبة في التبول ليلاً، كثرة التبول</li><li>خلل في الانتصاب، مشاكل في الغدد الثديية أو تضخم الغدد الثديية لدى الرجال</li><li>ألم، الشعور بتوعك</li><li>ألم في المفاصل أو العضلات، وألم في الظهر</li><li>زيادة الوزن أو انخفاض الوزن.</li></ul><p dir="RTL"><strong>نادرة (قد تحدث لدى 1 من كل 1000 مريض)</strong></p><ul dir="rtl"><li>ارتباك.</li></ul><p dir="RTL"><strong>نادرة جداً (قد تحدث لدى 1 من كل 10000 مريض)</strong></p><ul dir="rtl"><li>انخفاض عدد خلايا الدم البيضاء، انخفاض عدد الصفائح الدموية؛ ما قد يؤدي إلى التكدم غير معتادة أو النزف بسهولة</li><li>ارتفاع مستوى السكر في الدم (فرط سكر الدم)</li><li>اضطرابات عصبية التي قد تؤدي إلى ضعف العضلات، الحساسية المنخفضة للمحفزات اللمسية أو التنميل</li><li>تورم اللثة</li><li>تضخم المعدة (التهاب المعدة)</li><li>اختلال وظيفة الكبد، التهاب الكبد، اصفرار الجلد (اليرقان)، زيادة في أنزيمات الكبد؛ ما قد يؤثر على بعض الفحوصات الطبية</li><li>زيادة التوتر العضلي</li><li>تفاعلات التهابية للأوعية الدموية، غالبًا مع طفح جلدي</li><li>الحساسية للضوء.</li></ul><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>قشعريرة، تصلب، تثبت تعابير الوجه (ملامح قناعية)، بطء في الحركة، المشي غير المتوازن.</li></ul><p dir="RTL"><strong><em>الآثار الجانبية المرتبطة بتناول الكانديسارتان</em></strong></p><p dir="RTL"><strong>شائعة (قد تحدث لدى 1 من كل 10 مرضى)</strong></p><ul dir="rtl"><li>دوخة/الشعور بعدم الاتزان (دوار)</li><li>صداع</li><li>عدوى الجهاز التنفسي</li><li>ضغط الدم المنخفض. يمكن أن يؤدي إلى شعور بالإغماء أو الدوخة</li><li>تغيرات في نتائج فحص الدم: ارتفاع مستوى البوتاسيوم في الدم، خصوصًا إذا كنت تعاني بالفعل من مشاكل في الكلية أو فشل القلب. في الحالات الشديدة قد تلاحظ إرهاق، ضعف، نبضات قلب غير منتظمة، أو تنميل (&quot;التنمّل&quot;)</li><li>التأثير في وظائف الكلى، خصوصًا إذا كنت تعاني بالفعل من مشاكل في الكلية أو فشل القلب. في حالات نادرة جداً، قد يحدث فشل كلوي.</li></ul><p dir="RTL"><strong>نادرة جداً (قد تحدث لدى 1 من كل 10000 مريض)</strong></p><ul dir="rtl"><li>تورم في الوجه، الشفتين، اللسان، و/أو الحلق</li><li>انخفاض عدد خلايا الدم البيضاء أو الحمراء. قد تلاحظ إرهاق، عدوى، أو حمى</li><li>طفح جلدي، طفح مع نفطات (الشَّرَى).</li><li>حكة</li><li>ألم في الظهر، ألم في المفاصل أوالعضلات.</li><li>تغيرات في وظيفة الكبد، تشمل التهاب الكبد. قد تلاحظ إرهاقًا، اصفرار الجلد، اصفرار بياض العين، وأعراضًا تشبه الإنفلونزا.</li><li>سعال</li><li>غثيان</li><li>تغيرات في نتائج فحص الدم: انخفاض مستوى الصوديوم في الدم. في الحالات الشديدة، قد تلاحظ ضعفًا، نقصًا في الطاقة، أو تشنجات عضلية.</li></ul><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>إسهال.</li></ul><p>يرجى الاتصال بالطبيب، مقدم الرعاية الصحية، أو الصيدلي في حال اصبحت أي من الآثار الجانبية أكثر سوءاً أو في حال ظهور أية آثار جانبية لم تذكر في هذه النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;المواد الفعالة هي كانديسارتان سيليكسيتيل وأملوديبين بيسيلات.</p><p dir="RTL">يحتوي كل قرص من يونيجيا 8 ملغم/2.5 ملغم أقراص على 8 ملغم كانديسارتان سيليكسيتيل و3.47 ملغم أملوديبين بيسيلات تكافئ 2.5 ملغم أملوديبين.</p><p dir="RTL">يحتوي كل قرص من يونيجيا 8 ملغم/5 ملغم أقراص على 8 ملغم كانديسارتان سيليكسيتيل و6.93 ملغم أملوديبين بيسيلات تكافئ 5 ملغم أملوديبين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانيتول، ھیدروكسي بروبیل السيللیلوز، سيلليلوز بلوري مكروي، جليكول متعدد الايثيلين، كروسكارمیللوز الصودیوم، ستيرات المغنيسيوم وأكسيد الحديد الأصفر (في يونيجيا 8 ملغم/2.5 ملغم أقراص فقط) وأكسيد الحديد الأحمر (في يونيجيا 8 ملغم/5 ملغم أقراص فقط).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یونیجیا 8 ملغم/2.5 ملغم هي أقراص لونها أصفر فاتح كبسولية الشكل منقوش عليها &quot;JI&quot; على أحد الجانبين و&quot;152&quot; على الجانب الآخر في أشرطة برتقالية اللون من كلوريد متعدد الڤينيل/أكلار-ألومنيوم.</p><p dir="RTL">یونیجیا 8 ملغم/5 ملغم هي أقراص لونها أحمر فاتح كبسولية الشكل منقوش عليها &quot;JI&quot; على أحد الجانبين و&quot;153&quot; على الجانب الآخر في أشرطة برتقالية اللون من كلوريد متعدد الڤينيل/أكلار-ألومنيوم. &nbsp;</p><p dir="RTL">حجم العبوة: 30 قرص (3 أشرطة؛ يحتوي كل شريط على 10 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق، محرر التشغيلة والشركة المصنعة للمستحضر النهائي </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>بترخيص من </strong></p><p dir="RTL">شركة تاكيدا الدوائية المحدودة</p><p dir="RTL">أوساكا - اليابان</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الإمارات العربية المتحدة</p><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 08/2023، رقم النسخة: Un3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unisia 8 mg/2.5 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 8 mg candesartan cilexetil and 3.47 mg amlodipine besylate equivalent to 2.5 mg amlodipine. 
Excipient with known effect: Sodium. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. 

Light yellow capsule-shaped tablets, embossed with “JI” on one side and “152” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unisia is indicated as replacement therapy for essential hypertension in adults whose blood pressure is being adequately controlled with concomitant administration of amlodipine and candesartan cilexetil in the same dosage range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Patients should take the strength that corresponds to their previous treatment.</p><p>Different strengths of this medicinal product are available for the usual dosages: The dose of 8 mg candesartan cilexetil and 2.5 mg amlodipine once daily is achieved by administering one tablet of Unisia 8 mg/2.5 mg. &nbsp;</p><p>The dose of 8 mg candesartan cilexetil and 5 mg amlodipine once daily is achieved by administering one tablet of Unisia 8 mg/5 mg.</p><p>The maximum dose of candesartan cilexetil is 32 mg daily and the maximum dose of amlodipine is 10 mg daily.</p><p><em>Elderly (over 65 years)</em></p><p>The dose should be increased with caution (see sections 4.4 and 5.2).</p><p><em>Hepatic impairment</em></p><p>No dosage recommendations are available for patients with hepatic impairment. Unisia is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3, 4.4, and 5.2).</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance &gt; 15 ml/min; see sections 4.4 and 5.2). Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment.</p><p><em>Pediatric population</em></p><p>The safety and effectiveness of candesartan cilexetil/amlodipine besylate in children under 18 years of age have not yet been established. No data available.</p><p><strong>Method of administration</strong></p><p>The tablets can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active ingredients, to dihydropyridine derivatives or to any of the excipients listed in section 6.1. 
•	Severe hypotension. 
•	Shock (including cardiogenic shock). 
•	Obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis). 
•	Hemodynamically unstable heart failure following acute myocardial infarction. 
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6). 
•	Severe hepatic impairment and/or cholestasis. 
•	The concomitant use of Unisia with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).  


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Amlodipine</strong></p><p>The safety and efficacy of amlodipine in hypertensive crisis have not yet been confirmed.</p><p><em>Heart failure</em></p><p>Caution is advised in the treatment of patients with heart failure. In a long-term placebo-controlled study, there were increased reports of pulmonary edema in patients with severe heart failure (NYHA functional class III and IV) taking amlodipine compared with the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with chronic heart failure because these may increase the risk of future cardiovascular events as well as mortality.</p><p><em>Hepatic impairment</em></p><p>In patients with hepatic impairment, the half-life of amlodipine is prolonged and AUC values are elevated; there is no recommended dose. Amlodipine should therefore be started at the lower end of the dosing range in these patients and should be administered with caution, both when initiating therapy and when increasing the dose. In patients with severe hepatic impairment, slow dose titration and close monitoring may be necessary.</p><p><em>Elderly</em></p><p>In elderly patients, the dosage should be increased only with caution (see sections 4.2 and 5.2).</p><p><em>Renal impairment</em></p><p>Amlodipine may be used in such patients at usual doses. There is no correlation between the degree of renal impairment and changes in plasma amlodipine levels. Amlodipine is not dialyzable.</p><p><u>Candesartan</u></p><p><em>Renal impairment</em></p><p>As with other medicinal products that block the renin-angiotensin-aldosterone system, changes in renal function can be expected in susceptible patients treated with candesartan.</p><p>When candesartan is used in hypertensive patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is limited experience in patients with very severe renal impairment or end-stage renal impairment (Cl<sub>creatinine</sub> &lt; 15 ml/min). In these patients, candesartan should be carefully titrated with thorough monitoring of blood pressure.</p><p>Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and in patients with impaired renal function. During dose titration of candesartan, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine &gt;265 &mu;mol/l (&gt;3 mg/dl).</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers, or aliskiren increases the risk of hypotension, hyperkalemia, and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combines use of ACE inhibitors, angiotensin II receptor blockers, or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only happen under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE inhibitors and angiotensin II receptor antagonists should not be used concomitantly in patients with diabetic nephropathy.</p><p><em>Hemodialysis</em></p><p>During dialysis the blood pressure may be particularly sensitive to AT<sub>1</sub>-receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore candesartan should be carefully titrated with thorough monitoring of blood pressure in patients on hemodialysis.</p><p><em>Renal artery stenosis</em></p><p>Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.</p><p><em>Kidney transplantation</em></p><p>There is limited clinical evidence regarding candesartan use in patients who have undergone renal transplant.</p><p><em>Hypotension</em></p><p>Hypotension may occur during treatment with Candesartan Cilexetil in heart failure patients. It may also occur in hypertensive patients with intravascular volume depletion such as those receiving high dose diuretics. Caution should be observed when initiating therapy and correction of hypovolemia should be attempted.</p><p><em>Anesthesia and surgery</em></p><p>Hypotension may occur during anesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p><p><em>Aortic and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)</em></p><p>As with other vasodilators, special caution is indicated in patients suffering from hemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><em>Primary hyperaldosteronism</em></p><p>Patients with primary hyperaldosteronism will not generally respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin-aldosterone system.&nbsp;&nbsp; Therefore, the use of candesartan is not recommended in this population.</p><p><em>Hyperkalemia</em></p><p>Concomitant use of Candesartan Cilexetil with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin, co-trimoxazole also known as trimethoprim/sulfamethoxazole) may lead to increases in serum potassium in hypertensive patients. Potassium levels should be monitored as appropriate.</p><p>Hyperkalemia may occur in heart failure patients treated with candesartan. Periodic monitoring of serum potassium is recommended. The combination of an ACE inhibitor, a potassium-sparing diuretic (e.g., spironolactone), and candesartan is not recommended and should be considered only after careful evaluation of the potential benefits and risks.</p><p><em>General</em></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), acute hypotension, azotemia, oliguria, or, rarely, acute renal failure have been associated with treatment with other medicinal products that affect this system. The possibility of similar effects cannot be ruled out for AIIRAs.</p><p>As with any antihypertensive agent, an excessive drop in blood pressure could lead to myocardial infarction or stroke in patients with ischemic cardiomyopathy or ischemic cerebrovascular disease.</p><p>The antihypertensive effect of candesartan may be enhanced by other medicinal products with antihypertensive properties, whether prescribed as antihypertensives or for other indications.</p><p><em>Pregnancy</em></p><p>Treatment with AIIRAs should not be initiated during pregnancy. Patients planning pregnancy should be switched to an alternative antihypertensive treatment with an established safety profile for use in pregnancy, except where continued treatment with AIIRAs is considered essential.. When pregnancy is diagnosed, treatment with AIIRAs should be discontinued immediately and, if appropriate, alternative therapy should be initiated (see sections 4.3 and 4.6).</p><p><strong>Unisia</strong><strong> </strong><strong>contains sodium &nbsp;</strong></p><p>Unisia contains sodium. Each tablet conatins 0.57 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Interactions associated with amlodipine</strong></p><p><u>Effects of other medicinal products on amlodipine</u></p><p><em>CYP3A4 inhibitors</em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides such as erythromycin or clarithromycin, verapamil, or diltiazem) may result in a significant increase in amlodipine exposure with a resulting increased risk of hypotension. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Close monitoring of patients is therefore recommended and dose adjustment may be required.</p><p><em>CYP3A4 inducers</em></p><p>Co-administration of known CYP3A4 inducers may result in varying plasma concentration of amlodipine. Thus, blood pressure should be monitored and dose regulation considered, both during and after concomitant administration, particularly with potent CYP3A4 inducers (e.g., rifampicin, St. John&#39;s wort [Hypericum perforatum]).</p><p>The concomitant use of amlodipine with grapefruit or grapefruit juice is not recommended because it may increase the bioavailability of amlodipine in some patients. This could lead to increased blood pressure lowering effects</p><p><em>Dantrolene (infusion)</em></p><p>In animals, following administration of verapamil and intravenous dantrolene, lethal ventricular fibrillation and cardiovascular collapse associated with hyperkalemia are observed. Due to risk of hyperkalemia, it is recommended that co-administration of calcium channel blockers such as amlodipine be avoided in those patients susceptible to or being treated for malignant hyperthermia.</p><p><u>Effects of amlodipine on other medicinal products</u></p><p>The antihypertensive effect of amlodipine enhances the blood pressure lowering effect of other antihypertensive medicinal products.</p><p>In clinical interaction studies, amlodipine showed no effect on the pharmacokinetics of atorvastatin, digoxin, or warfarin. &nbsp;</p><p><em>Tacrolimus</em></p><p>There is a risk of increased tacrolimus blood levels from co-administration of amlodipine. To avoid tacrolimus toxicity, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p><em>mTOR(mechanistic target of rapamycin) inhibitors</em></p><p>mTOR inhibitors, such as sirolimus, temsirolimus, and everolimus, are CYP3A substrates, and amlodipine is a weak CYP3A inhibitor. Amlodipine may increase mTOR inhibitor exposure when used concomitantly with mTOR inhibitors.</p><p><em>Ciclosporin</em></p><p>No drug interaction studies have been conducted with ciclosporin and amlodipine in healthy volunteers or other populations. An exception is renal transplant patients, where variable trough concentration increases (average 0% - 40%) of ciclosporin were observed. In renal transplant patients, monitoring ciclosporin levels should be considered while using amlodipine and the dose of ciclosporin reduced if necessary.</p><p><em>Simvastatin</em></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. In patients on amlodipine, limit the dose of simvastatin to 20 mg daily.</p><p><strong>Interactions associated with candesartan</strong></p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>Data from clinical trials has shown that dual blockade of the renin-angiotensin- aldosterone system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers, or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalemia, and decreased renal function (including acute renal failure) compared with using a single agent acting on the RAAS (see sections 4.3, 4.4, and 5.1).</p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported with concomitant use of lithium and ACE inhibitors. A similar effect may occur with AIIRAs. Using candesartan with lithium is not recommended.</p><p>If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><em>NSAIDs</em></p><p>When AIIRAs are administered concomitantly with nonsteroidal anti-inflammatory medicinal products (NSAIDs) (i.e., selective COX-2 inhibitors, acetylsalicylic acid [&gt; 3 g/day], and nonselective NSAIDs), the antihypertensive effect may be attenuated.</p><p>As with ACE inhibitors, concomitant administration of AIIRAs and NSAIDs may result in an increased risk of worsening renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with pre-existing poor renal function. The combination should be administered with caution, especially in the elderly.</p><p>Patients should be adequately hydrated, and monitoring of renal function should be considered after initiation of concomitant therapy and periodically thereafter.</p><p><em>Potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, and other substances that can increase potassium level</em></p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, or other medicinal products (e.g., heparin) may increase potassium levels.</p><p>Potassium levels should be monitored as appropriate (see section 4.4).</p><p>Compounds that have been studied in clinical pharmacokinetics studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (ie. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine, and enalapril. No clinically significant pharmacokinetic interactions with these medicinal products were observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Candesartan cilexetil/amlodipine besylate is not recommended in the first trimester of pregnancy because no data is available and the safety profile for amlodipine and candesartan has not yet been confirmed.</p><p>Use during early pregnancy is recommended only when safer alternative therapies are not available and the disease poses a higher risk to the mother and fetus.</p><p>Unisia is contraindicated during the second and third trimesters of pregnancy due to the candesartan it contains.</p><p><u>Amlodipine</u></p><p>The safety of amlodipine during pregnancy has not yet been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p><u>Candesartan</u></p><p>The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>No conclusive epidemiologic data is available regarding teratogenicity risk following exposure to ACE inhibitors during the first trimester of pregnancy; however, a slightly increased risk cannot be ruled out. Although there is no controlled epidemiologic data on the risk from angiotensin II receptor antagonists (AIIRAs), similar risks may exist for this class of medicinal products. Unless continued AIIRA therapy is considered essential, patients planning to become pregnant should be switched to an alternative antihypertensive therapy with an appropriate safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be discontinued immediately and, if appropriate, alternative therapy should be initiated.</p><p>Therapy with AIIRAs during the second and third trimesters of pregnancy is known to induce human fetotoxicity (decreased renal function, oligohydramnios, delayed cranial ossification) and neonatal toxicity (renal failure, hypotension, hyperkalemia) (see also section 5.3). Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound examinations of renal function and skull are recommended.</p><p>Infants whose mothers have taken AIIRAs should be frequently reassessed for hypotension (see also sections 4.3 and 4.4).</p><p><strong>Breast-feeding</strong></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose that passes to the infant is estimated to be in an interquartile range of 3% to 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown.</p><p>Because no evidence is available on the use of candesartan during breast-feeding, candesartan cilexetil/amlodipine besylate tablets are not recommended; alternative antihypertensive therapy with an established safety profile during breast-feeding is preferable, especially while nursing a newborn or preterm infant.</p><p><strong>Fertility</strong></p><p><u>Amlodipine</u></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients being treated with calcium channel blockers. Clinical data regarding the potential effect of amlodipine on fertility is still insufficient. In one study on rats, male fertility was affected (see section 5.3).</p><p><u>Candesartan</u></p><p>Animal studies have shown that candesartan cilexetil had no effect on fertility in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unisia has a moderate impact on ability to drive and use machines. If patients under treatment with candesartan cilexetil/amlodipine besylate suffer from dizziness, headache, fatigue or nausea, responsiveness may be impaired. Caution is indicated here, especially when treatment first starts.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects previously reported with the individual compounds (amlodipine or candesartan) may potentially be an undesirable effect for candesartan cilexetil/amlodipine besylate.</p><p><strong>Undesirable effects associated with amlodipine</strong></p><p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions during treatment are drowsiness, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, edema, and fatigue.</p><p>The following adverse reactions have been observed and reported during treatment with amlodipine with the following frequencies: very common (&ge; 1/10), common (&ge; 1/100 to &lt;1/10), occasional (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (frequency cannot be estimated based on available data).</p><p>In each frequency group, undesirable effects are listed in order of decreasing severity.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable effect</strong></p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>Very rare</p></td><td><p>Leukocytopenia, thrombocytopenia</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Very rare</p></td><td><p>Allergic reactions</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Very rare</p></td><td><p>Hyperglycemia</p></td></tr><tr><td rowspan="2"><p>Psychiatric disorders</p></td><td><p>Uncommon</p></td><td><p>Depression, mood swings (including anxiety), insomnia</p></td></tr><tr><td><p>Rare</p></td><td><p>Confusion</p></td></tr><tr><td rowspan="4"><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Drowsiness, dizziness, headache (especially at the beginning of treatment)</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Tremor, dysgeusia, syncope, hypoesthesia, paresthesia</p></td></tr><tr><td><p>Very rare</p></td><td><p>Hypertonia, peripheral neuropathy</p></td></tr><tr><td><p>Not known</p></td><td><p>Extrapyramidal disorder</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>Common</p></td><td><p>Visual disturbance (including diplopia)</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>Uncommon</p></td><td><p>Tinnitus</p></td></tr><tr><td rowspan="3"><p>Cardiac disorders</p></td><td><p>Common</p></td><td><p>Palpitations</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Arrhythmia (including bradycardia, ventricular tachycardia, and atrial fibrillation)</p></td></tr><tr><td><p>Very rare</p></td><td><p>Myocardial infarction</p></td></tr><tr><td rowspan="3"><p>Vascular disorders</p></td><td><p>Common</p></td><td><p>Flushing</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Hypotension</p></td></tr><tr><td><p>Very rare</p></td><td><p>Vasculitis</p></td></tr><tr><td rowspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Common</p></td><td><p>Dyspnea</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Cough, rhinitis</p></td></tr><tr><td rowspan="3"><p>Gastrointestinal disorders</p></td><td><p>Common</p></td><td><p>Abdominal pain, nausea, dyspepsia, altered bowel habits (including diarrhea and constipation)</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Vomiting, dry mouth</p></td></tr><tr><td><p>Very rare</p></td><td><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td><p>Hepato-biliary disorders</p></td><td><p>Very rare</p></td><td><p>Hepatitis, jaundice, increase in hepatic enzymes*</p></td></tr><tr><td rowspan="3"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Uncommon</p></td><td><p>Alopecia, purpura, skin discoloration, hyperhidrosis, pruritus, rash, exanthema, urticaria</p></td></tr><tr><td><p>Very rare</p></td><td><p>Angioedema, erythema exsudativum multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke edema, photosensitivity</p></td></tr><tr><td><p>Not known</p></td><td><p>Toxic epidermal necrolysis</p></td></tr><tr><td rowspan="2"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td><p>Common</p></td><td><p>Ankle swelling, muscle cramps</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Arthralgia, myalgia, back pain</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Uncommon</p></td><td><p>Micturition disorder, nocturia, increased urinary frequency</p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td><p>Uncommon</p></td><td><p>Impotence, gynecomastia</p></td></tr><tr><td><p>General disorders and</p></td><td><p>Very common</p></td><td><p>Edema</p></td></tr><tr><td rowspan="2"><p>administration site conditions</p></td><td><p>Common</p></td><td><p>Fatigue, asthenia</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Chest pain, pain, malaise</p></td></tr><tr><td><p>Investigations</p></td><td><p>Uncommon</p></td><td><p>Weight gain, weight loss</p></td></tr></tbody></table><p>*mostly consistent with cholestasis Adverse reactions</p><p><strong>Associated with candesartan</strong></p><p><u>Treatment for hypertension</u></p><p>In controlled clinical trials, adverse reactions were mild and transient. The overall incidence of adverse events showed no association with dose or age. Discontinuation of treatment due to adverse events were similar between candesartan cilexetil (3.1%) and placebo (3.2%).</p><p>In a pooled analysis of data from clinical trials in hypertensive patients, adverse reactions with candesartan cilexetil were defined based on the frequency of adverse events with candesartan cilexetil being at least 1% higher than the frequency observed with placebo. By this definition, the most commonly reported adverse events were dizziness/vertigo, headache, and respiratory infection.</p><p>The table below presents adverse reactions from clinical trials and post-marketing experience. The frequency shown in the tables throughout section 4.8 are: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Respiratory infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperkalemia, hyponatremia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness/vertigo, headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Diarrhea</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Elevated liver enzymes, abnormal hepatic function or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal muscle, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure in susceptible patients (see section 4.4)</p></td></tr></tbody></table><p><em>Laboratory findings</em></p><p>In general, there were no clinically important effects of candesartan cilexetil on routine laboratory variables. As with other renin-angiotensin-aldosterone system inhibitors, there was a small decrease in hemoglobin. Patients receiving candesartan cilexetil usually do not require routine monitoring of laboratory variables. However, in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>There is no experience of overdose with candesartan cilexetil/amlodipine besylate. Candesartan overdose is likely to manifest as symptomatic hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and possibly reflex tachycardia. Marked and possibly persistent systemic hypotension up to and including shock with fatal outcome have been reported. In individual case reports of overdoses (of up to 672 mg candesartan cilexetil), patients recovered fully.</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48 hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p><strong>Management</strong></p><p>If ingestion was recent, induced vomiting or gastric lavage may be considered. In healthy volunteers, administration of activated charcoal up to two hours after taking 10 mg of amlodipine has been shown to reduce the amlodipine absorption rate. Clinically significant hypotension due to candesartan cilexetil/amlodipine besylate overdose requires active cardiovascular support, including close monitoring of cardiac and respiratory function, elevation of extremities, and control of fluid balance and urine output.</p><p>A vasoconstrictor may be administered to restore vascular tone and blood pressure unless contraindicated. Intravenous calcium gluconate may be useful in reversing the effects of calcium channel blockade.</p><p>For both candesartan and amlodipine, dialysis is not likely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, and calcium channel blockers, ATC code: C09DB07.</p><p>Unisia combines two antihypertensive agents with complementary mechanisms of action to control blood pressure in patients with essential hypertension: Amlodipine belongs to the class of medicinal products called calcium antagonists and candesartan to the class of angiotensin II antagonists. The combination of these agents has an additive antihypertensive effect, lowering blood pressure more than either compound alone.</p><p><u>Amlodipine</u></p><p>Amlodipine is a dihydropyridine-type calcium antagonist that inhibits the influx of calcium ions into cardiac muscle cells and vascular smooth muscle cells (slow calcium channel blocker; calcium channel blocker).</p><p>The antihypertensive action of amlodipine is due to the direct relaxation of vascular smooth muscle. The precise mechanism by which amlodipine relieves angina is not yet fully known; however, it reduces ischemia through the following two actions:</p><p>1.&nbsp; Peripheral arterioles are dilated. This lowers the peripheral resistance (afterload) against which the heart must work. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen demand.</p><p>2.&nbsp; It is likely that amlodipine causes dilatation of coronary arteries and arterioles, both in normal and ischemic regions. This dilatation increases myocardial oxygen delivery in patients with spasm of the coronary arteries (Prinzmetal&#39;s or variant angina).</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval.&nbsp; Due to the slow onset of action, acute hypotension is not expected with amlodipine administration.</p><p>No adverse metabolic effects or changes in lipid levels occurred with amlodipine. It is suitable for use in patients with asthma, diabetes and gout.</p><p><u>Candesartan</u></p><p><em>Mechanism of action</em></p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension, heart failure, and other cardiovascular disorders. It also plays a role in the pathogenesis of end-organ hypertrophy and damage. The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis, and stimulation of cell growth, are mediated via the type 1 (AT1) receptor.</p><p><em>Pharmacodynamic effects</em></p><p>Candesartan cilexetil is a prodrug suitable for oral use. During absorption from the gastrointestinal tract, it is rapidly converted to the active form candesartan by ester hydrolysis.</p><p>Candesartan is an AIIRA, selective for the AT1 receptors, that binds tightly to and dissociates slowly from the receptor. It has no agonistic activity.</p><p>Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin. It has no effect on ACE and no potentiation of bradykinin or substance P. In controlled clinical trials comparing candesartan and ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan neither binds to nor blocks other hormone receptors or ion channels known to be important in cardiovascular regulation. Antagonism of the angiotensin II (AT1) receptors results in a dose-dependent increase in plasma renin, angiotensin I, and angiotensin II levels and a decrease in plasma aldosterone concentration.</p><p><em>Clinical efficacy and safety in hypertension</em></p><p>In hypertension, candesartan produces a dose-dependent, long-lasting reduction in arterial blood pressure. The antihypertensive effect is due to decreased systemic peripheral resistance, without reflex increase in heart rate. There is no evidence of severe or exaggerated first-dose hypotension or rebound effect after cessation of therapy.</p><p>After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs within 2 hours. With continuous therapy, antihypertensive effects are usually achieved within four weeks at any dosage and is sustained during long-term therapy. According to a meta-analysis, the average incremental effect of increasing the dose from 16 mg to 32 mg once daily was small. Taking into account inter-individual variability, an above-average effect can be expected in some patients. Candesartan cilexetil once daily produces effective and consistent blood pressure lowering over 24 hours with little difference between the maximum and trough effects during the dosing interval. The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomized double-blind studies involving a total of 1,268 patients with mild to moderate hypertension. The trough reduction in blood pressure (systolic/diastolic) was 13.1/10.5 mmHg with candesartan cilexetil 32 mg once daily and 10.0/8.7 mmHg with losartan-potassium 100 mg once daily (difference in blood pressure reduction 3.1/1.8 mmHg, p &lt; 0.0001/p &lt; 0.0001).</p><p>When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive. An enhanced antihypertensive effect is also observed when candesartan cilexetil is combined with amlodipine or felodipine.</p><p>Medicinal products that block the renin-angiotensin-aldosterone system have a less pronounced antihypertensive effect in black patients (usually a population with low renin levels) than in non-black patients. This is also the case for candesartan. In an open-label clinical trial in 5,156 patients with diastolic hypertension, blood pressure reduction during candesartan therapy was significantly less in black than in non-black patients (14.4/10.3 mmHg vs. 19.0/12.7 mmHg, p &lt; 0.0001/p &lt; 0.0001).</p><p>Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate, while renal vascular resistance and filtration fraction are reduced. In a 3-month clinical trial in hypertensive patients with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced urinary albumin excretion (albumin/creatinine ratio, mean 30%; 95% CI: 15-42%). There is currently no data on the effect of candesartan on the progression to diabetic nephropathy.</p><p>The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg) once daily on cardiovascular morbidity and mortality were analyzed in a randomized clinical trial on 4,937 elderly patients (70-89 years; 21% 80 or older) with mild to moderate hypertension over an mean of 3.7 years (Study on Cognition and Prognosis in the Elderly). Patients received candesartan cilexetil or placebo and in addition, other antihypertensive treatment as needed. Blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary end point, major cardiovascular events (cardiovascular mortality, non-fatal stroke, and non-fatal myocardial infarction). There were 26.7 events per 1,000 patient-years in the candesartan group versus 30.0 events per 1,000 patient-years in the control group (relative risk 0.89; 95% CI: 0.75 to 1.06; p = 0.19).&nbsp; &nbsp;</p><p>Two large randomized controlled trials (&quot;ONTARGET&quot; [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and &quot;VA NEPHRON-D&quot; [The Veterans Affairs Nephropathy in Diabetes]) examined the concomitant use of an ACE inhibitor with an angiotensin II receptor antagonist.</p><p>The &quot;ONTARGET&quot; study was conducted in patients with a history of cardiovascular or cerebrovascular disease or type 2 diabetes mellitus with established end-organ damage. The &quot;VA NEPHRON-D&quot; study was conducted in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies showed no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while a higher risk of hyperkalemia, acute kidney injury, and/or hypotension was observed compared with monotherapy. Given their comparable pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor antagonists. ACE inhibitors and angiotensin II receptor antagonists should not be used concomitantly in patients with diabetic nephropathy.</p><p>The &quot;ALTITUDE&quot; study (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) investigated whether the use of aliskiren in addition to standard therapy with an ACE inhibitor or angiotensin II receptor antagonist has an added benefit in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early due to an increased risk of adverse events. Both cardiovascular death and stroke occurred numerically more frequently in the aliskiren group than in the placebo group, as did adverse events and serious adverse events of interest (hyperkalemia, hypotension, renal dysfunction).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption and distribution</strong></p><p><em>Amlodipine</em></p><p>Following oral administration of therapeutic doses, amlodipine is well absorbed, with peak blood concentration reached after 6 to 12 hours. The absolute bioavailability in humans is about 64 to 80%. The volume of distribution is approximately 21 l/kg. <em>In vitro, </em>approximately 97.5% of circulating amlodipine was shown to be bound to plasma proteins. The bioavailability of amlodipine is not affected by food intake.</p><p><em>Candesartan</em></p><p>Following oral administration, candesartan cilexetil is converted to the active form candesartan. The absolute bioavailability of candesartan after an oral solution of candesartan cilexetil is approximately 40%. The relative bioavailability of the tablet formulation, compared to the same oral solution, is approximately 34% with very little variability. The estimated absolute bioavailability of the tablet is therefore 14%. The mean peak serum concentration (C<sub>max</sub>) is reached 3-4 hours following tablet intake. Candesartan serum concentrations increase linearly with increasing doses within the therapeutic dosage range.</p><p>No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration/time curve (AUC) of candesartan is not significantly affected by food.</p><p>Candesartan is highly bound to plasma proteins (greater than 99%). The apparent volume of distribution of candesartan is 0.1 l/kg.</p><p>The bioavailability of candesartan is not affected by food.</p><p><strong>Biotransformation and elimination</strong></p><p><em>Amlodipine</em></p><p>The terminal plasma half-life is about 35 to 50 hours, suggesting once-daily dosing. Amlodipine is largely metabolized in the liver to inactive metabolites. In urine, 10% of the substance is excreted unchanged and 60% of the metabolites.</p><p><em>Candesartan</em></p><p>Candesartan is eliminated mainly unchanged via urine and bile and only to a minor extent by hepatic metabolism (CYP2C9). Available interaction studies show no effects on CYP2C9 and CYP3A4. Based on in vitro data, no interactions would be expected <em>in vivo </em>with substances whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. The terminal half-life of candesartan is approximately 9 hours. There is no accumulation following multiple doses.</p><p>The total plasma clearance of candesartan is approximately 0.37 ml/min/kg with a renal clearance of approximately 0.19 ml/min/kg. Renal elimination of candesartan takes place by both glomerular filtration and active tubular secretion. Following an oral dose of <sup>14</sup>C-labeled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite, while approximately 56% of the dose is recovered in the feces as candesartan and 10% as an inactive metabolite.</p><p><strong>Pharmacokinetics in special populations</strong></p><p><u>Hepatic impairment</u></p><p><em>Amlodipine</em></p><p>Very limited clinical data are available on the use of amlodipine in patients with hepatic impairment. Patients with liver failure exhibit decreased clearance of amlodipine, resulting in a prolonged half-life and an increase in AUC of approximately 40% to 60%.</p><p><em>Candesartan</em></p><p>In two studies, both of which included patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other (see section 4.2). There is no experience in patients with severe hepatic impairment.</p><p><u>Elderly</u></p><p><em>Amlodipine</em></p><p>The time to reach peak plasma concentrations is the same in elderly and younger patients. In elderly patients, amlodipine clearance appears to be decreased, resulting in an increase in AUC and elimination half-life. The increase in AUC and elimination half-life in patients with heart failure was in line with expectations in relation to the age group studied.</p><p><em>Candesartan</em></p><p>In the elderly (over 65 years of age), C<sub>max</sub> and AUC of candesartan are increased by approximately 50% and 80%, respectively, compared to young subjects. However, the blood pressure response and the incidence of adverse events are similar after administration of the dose of candesartan cilexetil in young and elderly patients (see section 4.2).</p><p><u>Renal impairment</u></p><p><em>Amlodipine</em></p><p>There is no correlation between the degree of renal impairment and changes in plasma amlodipine levels. Amlodipine is not dialyzable.</p><p><em>Candesartan</em></p><p>In patients with mild to moderate renal impairment, C<sub>max</sub> and AUC of candesartan increased by approximately 50% and 70%, respectively, during repeated dosing compared with patients with normal renal function; t<sub>1/2</sub> was unchanged. The corresponding changes in patients with severe renal function impairment were approximately 50% and 110%, respectively. The terminal t<sub>1/2</sub> of candesartan was approximately doubled in patients with severe renal impairment. The AUC of candesartan in dialysis patients was similar to that in patients with severe renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Amlodipine</u></p><p><em>Reproductive toxicity</em></p><p>In reproductive toxicity studies, overdue birth, extended labor, and reduced offspring survival rates were observed in rats and mice at doses approximately 50 times higher than the maximum recommended human dose based on mg/kg.</p><p><em>Impairment of fertility</em></p><p>Doses up to 10 mg/kg/day (8 times* the maximum recommended dose of 10 mg in humans, based on mg/m&sup2;) showed no effects on fertility in rats treated with amlodipine (males: 64 days; females: 14 days before mating). In another study in rats, in which male rats were treated for 30 days with amlodipine besylate at doses comparable to those in humans, based on mg/kg, both a decrease in follicle-stimulating hormone and testosterone in plasma and a decrease in sperm density and a decrease in mature spermatids and Sertoli cells were found.</p><p><em>Carcinogenesis, mutagenesis</em></p><p>There was no evidence of carcinogenicity in rats and mice fed amlodipine at doses of 0.5, 1.25, and 2.5 mg/kg daily in the diet for two years. The highest dose (for mice, the same as, and for rats, twice* the maximum recommended human dose of 10 mg, based on mg/m&sup2;) was close to the maximum dose tolerated by mice but not by rats.</p><p>Mutagenicity studies revealed no medicinal product related effects at the gene or chromosome levels.</p><p>*Based on a 50 kg patient.</p><p><u>Candesartan</u></p><p>Fetotoxicity has been observed in late pregnancy (see section 4.6).</p><p>At clinically relevant doses, there was no evidence of abnormal systemic or target organ toxicity. In preclinical safety studies, candesartan affected kidney and red blood cell parameters at high doses in mice, rats, dogs, and monkeys. Candesartan caused a decrease in red blood cell parameters (erythrocytes, hemoglobin, hematocrit). Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules; increased plasma concentrations of urea and creatinine) have been induced by candesartan, which may be a consequence of the hypotensive effect leading to changes in renal perfusion. In addition, candesartan induced hyperplasia/hypertrophy of juxtaglomerular cells. It is believed that these changes caused by the pharmacological action of candesartan. For therapeutic doses of candesartan in humans, hyperplasia/hypertrophy of renal juxtaglomerular cells appears to be of no relevance.</p><p>There was no evidence of carcinogenicity.</p><p>Data from in vitro and in vivo mutagenicity tests indicate that candesartan does not exert mutagenic or clastogenic activities under conditions of clinical use.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydroxy propyl cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Polyethylene glycol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Croscarmellose sodium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Yellow iron oxide&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Orange PVC/Aclar-aluminum blisters.</p><p>Pack size: 30 Tablets (3 blisters; each blister contains 10 tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>